Use of intravenous sodium bicarbonate in neonatal intensive care units in Italy: a nationwide survey.

Luca Massenzi (lumass2001@yahoo.it)  
Ospedale San Giovanni Calibita Fatebenefratelli

Roberto Aueri  
Ospedale Sant'Eugenio, Rome

Silvia Donno  
INVALSI

Rocco Agostino  
Casa di Cura, Villa Margherita, Roma

Andrea Dotta  
Ospedale Pediatrico Bambino Gesu

Research

Keywords: Infant, Newborn, Sodium Bicarbonate, Acid-Base imbalance, Surveys and Questionnaires, Drug Therapy

DOI: https://doi.org/10.21203/rs.3.rs-48558/v2

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Metabolic Acidosis (MA) is a disturbance of the acid-base balance that can occur in preterm and critically ill term neonates due to different etiologies. Intravenous sodium bicarbonate (SB) has been traditionally used to correct such unbalance, despite the lack of evidence about its safety and efficacy. In literature, reported undesirable effects of treatment with SB in neonates include worsening of intracellular acidosis, impairment of myocardial function, cerebral blood flow fluctuations and intracranial hemorrhage. A national survey was conducted by the Neonatal Pharmacotherapy Study Group of the Italian Society of Neonatology with the aim to assess and describe attitudes and practices concerning the use of SB, particularly for the treatment of MA in Italian NICUs.

**Methods:** A questionnaire regarding treatment of MA and SB prescription habits was sent to the directors of 120 Italian NICUs from June 2017 to March 2018.

**Results:** The survey response rate was 97.5% (117/120 centers). Findings showed that in 55% of the surveyed NICUs (64/117 units) it is common practice to correct MA with intravenous SB. On the other hand, the remaining 45% of the units try to solve the metabolic disturbances adopting different approaches (improving perfusion, adjusting ventilation parameters or increasing blood volume). Moreover, to prevent the occurrence of MA, 37.6% of the NICUs (44/117) include buffer salts (lactate, acetate or both) in parenteral nutrition prescriptions. SB is also used as a treatment for other conditions, mainly pathologies with bicarbonate loss and tubular acidosis (respectively in 53.8% and 32.5% of the NICUs).

**Conclusion:** This survey showed how SB is a commonly used treatment for MA in more than half of Italian NICUs, with indications and prescription criteria that significantly vary across centers. Based on current knowledge, it is reasonable to suggest that the management of neonatal MA should be firstly directed to identify the underlying disorders. Thus, the use of SB should be reserved only for selected cases, also considering the severity of SB adverse effects and the lack of evidence about its efficacy. Guidance for the management of MA is required to harmonize practices and reduce the use of potentially inappropriate and unsafe treatments.

**Background**

Despite being a common and largely debated issue, the management of neonatal metabolic acidosis (MA) still represents a challenge for clinicians, mainly due to the lack of evidence suggesting the most suitable and effective treatment. Therapeutic uncertainty can be mostly attributed to the different pathogenic pathways at the origin of MA: immaturity of the renal system, perinatal asphyxia, hypovolemia, sepsis, congenital heart diseases, renal or gastrointestinal losses and inborn errors of the metabolism, among others [1, 2]. The historically established empiric correction of MA with intravenous sodium bicarbonate (SB) is a controversial and largely debated practice. Indeed, it is understandable that one single drug may not be effective for such a large number of different etiologies. Moreover, current
evidence suggests that intravenous SB could represent a harmful treatment for patients with MA. Although numerous reports showed significant negative effects due to SB infusions, such as fluctuations in cerebral and cardiovascular hemodynamic [3, 4], increased rates of severe intraventricular hemorrhage (IVH) and mortality [5], SB is still used for treating MA in many neonatal intensive care units, as reported in a European survey conducted by Saenz P. et al in 2011. The authors themselves commented that their study indicated the presence of a “gap between scientific evidence and clinical practice” [6].

The aim of this study was to investigate the attitude and practices related to the use of intravenous SB with particular attention to the treatment of MA in Italian NICUs. For this purpose, in 2017, a national survey was carried out by the Neonatal Pharmacotherapy study group of the Italian Society of Neonatology (SIN).

**Methods**

We conducted a questionnaire-based study across Italian NICUs from June 2017 to March 2018.

**Questionnaire**

A 14-item questionnaire was developed by the Neonatal Pharmacology Study Group of the SIN. The questionnaire inquired about: NICU characteristics (volume of activity); treatment of MA (use of intravenous SB or alternative therapeutic strategies); SB dosage, preparation and administration; presence of buffer systems in the parenteral nutrition (PN); use of intravenous SB for other conditions. All questions were loaded on Google Forms Website (Google Inc., CA/USA), a free tool for creating online survey forms. The survey form was pre-tested for clarity purposes by other members of the study group. The questionnaire required about 15 minutes to be filled in and sent.

**Web-based survey**

Email addresses of the directors of the Italian NICUs were initially collected from the database of the SIN administrative office, after receiving consent for data utilization from the board of the society. In June 2017 a cover letter was sent to the directors of the NICUs requesting to complete and submit the online questionnaire available at the hyperlink https://goo.gl/forms/nMn3KTyNb6xNQv9K2 (File S1). In September 2017, considering that only 49 units had submitted the completed questionnaire, a review of the NICU directors’ contact list was carried out by LM and RA, and a new letter was sent to all directors, including those whose contacts resulted as being previously missing, incorrect or obsolete (File S2). In January 2018, all non-responders received a reminder email. Those who did not reply were finally contacted by phone and encouraged to participate in the survey. Data collection ended in March 2018. Participation was voluntary, and no financial rewards, nor other incentives were offered for the survey. The identity of each NICU director was kept confidential throughout the data collection and analysis.

**Statistical analysis**
By means of Google Forms (Google Inc., CA/USA), the questionnaires were converted into an Excel file (Microsoft, Seattle, WA). Subsequently, the questionnaires and the automatically generated file were re-checked for possible inconsistencies before inclusion in the database to be analyzed.

Statistical analysis consisted of descriptive statistics: continuous variables are presented as mean values ± standard deviation (SD); categorical variables are presented as absolute and relative frequencies (%). Data are provided as absolute numbers and relative frequencies (%). The \( \chi^2 \) test or Fisher’s exact test was used to compare differences in categorical variables among groups. A \( p \) values less than 0.05 was considered statistically significant, and \( p \)-values were based on two-tailed tests. Statistical analysis was performed using SPSS for Windows (SPSS, Inc., Chicago, IL).

**Results**

The overall survey response rate was 97.5% (117/120 contacted units). All the 117 filled in questionnaires were included in the analysis.

**NICU features**

Of the 117 investigated NICUs, the majority (83.8%) reside in perinatal centers that take care of more than 1,000 neonates per year, 39% with 1,000-2,000 births/year and 45% with more than 2,000 births/year. Four NICUs (3.4%) hospitalize only out-born patients; meanwhile, the remaining 12.8% (15/117) is active with less than 1,000 births/year.

**Use of intravenous SB for treatment of MA**

More than half of the surveyed NICUs (54.7%; 64/117) answered that in their unit it is a common practice to correct MA with intravenous SB. No significant differences were found among centers with different characteristics (\( p \) value=0.51), as shown in Figure 1.

Regarding whether a pH threshold was considered upon deciding to correct MA with SB, 51.6% of centers answered that they treat at pH values <7.2 (32/62) and 33.9% at pH <7.1 (21/62). Concerning Base Excess (BE) value thresholds, 69.8% of NICUs (44/63) answered to consider BE values ≤-10 and 17.5% (44/63) BE values ≤-8 to treat MA with intravenous SB. Lactate values instead were not taken into account for the treatment on behalf of 75.8% of centers (47/62). Results about blood gas analyses criteria used for MA correction with SB are presented in Table 1.

**SB dosage, preparation and administration**

69.8% of NICUs (44/63) calculate the SB dose to be administered using the formula "\( ml \ of \ SB = kg \times BE \times 0.3 / 2 \);" 12.7% of NICUs (8/63) instead use the formula "\( ml \ of \ SB= kg \times BE \times 0.3 / 3 \);" whereas 9.5% of NICUs (6/63) prefer to use a “full dose” ("\( ml \ of \ SB = kg \times BE \times 0.3 \)."
Before intravenous administration, 90.5% of the units (57/63) dilute SB with distilled water, while 4.3% of units (5/63) use normal saline. Moreover, the majority of NICUs (87.3%; 55/63) adopts a 1:1 dilution ratio, with only eight units using different ratios (1:2 in 6 units, 1:3 in 1 unit, whereas another unit answered “other”).

61.3% of NICUs (38/62) administer SB by means of a slow 30-60 minute intravenous infusion; 27.4% (17/62) prefer to provide SB in “pushes” within 30 minutes; 8.1% (5/62) use both “pushes” and “slow infusions”, while only 2 units (3.2%) administer SB in 3 to 4 hour long infusions.

Finally, cases of lesions due to SB extravasations were reported by 8.5% (10/117) of units.

SB dose, preparation and administration practices adopted among Italian NICUs are summarized in Table 2.

**Therapeutic strategies for treating MA**

All the 53 NICUs, where the treatment of MA with SB is not a common practice, use one or more therapeutic strategies to correct MA (Figure 2A-2B). Ninety-two percent of units (49/53) answered that they turn to perfusion improvement; 68% (36/53) increase the circulating volume with boluses of fluids; 64% (34/53) adjust mechanical ventilation parameters; 4% (2/53) modify parenteral nutrition composition.

**Buffer salts in PN**

62.4% of the participating NICUs (73/117) do not provide buffer systems in PN. On the contrary, 27.4% of centers (32/117) add acetate to the PN, three units (2.6%) adopt lactate, while 9 NICUs (7.7%) administer both lactate and acetate. There is a trend toward a greater use of buffer salts in the units with higher levels of activity, however the difference is not significant ($p$ value= 0.76), Figure 3.

**Use of intravenous SB for other conditions**

Metabolic acidosis represents the final result of several illnesses capable of determining an imbalance of acid-base equilibrium. In our research, fifty-six percent of surveyed NICUs (66/117) provide intravenous SB even to treat some conditions not immediately related to MA. The most common scenarios are represented by pathologies with bicarbonate losses (53.8%; 63/117 units) and tubular acidosis (32.5%; 38/117 units).

There were no significant differences in the responses among units with different levels of activity (<1000 births/year, 1000-2000 births/year, >2000 births/year, and only outborn). However, the heterogeneity in sample size of the four analyzed groups can be noted.

**Discussion**
MA is an acid-base imbalance that can occur acutely or chronically, characterized by a primary reduction in the serum concentration of bicarbonate (HCO₃⁻), a secondary decrease in the arterial partial pressure of carbon dioxide (PaCO₂), and a reduction in blood pH [7]. MA is a common finding in the critically ill infant and can be determined by a number of different etiologies, other than renal and gastrointestinal bicarbonate losses (in which the deficit correction with SB has been advocated by several authors [2,3]). The results of our survey show that more than half of Italian NICUs (54.7%) routinely use SB to treat MA. In the above-mentioned European survey, 42.2% of interviewed neonatologists would have administered SB in the case of an asphyxiated term neonate with severe combined metabolic and respiratory acidosis, with remarkable differences in practices among European countries (the rate of SB use in Italy corresponded to about 40%) [6].

The practice of treating neonatal MA with intravenous SB, was first reported in 1963 by Usher [8], who showed that an early infusion of a 10% glucose solution plus 5-15 mEq/dl of SB resulted in a considerable reduction in mortality among treated neonates. From that moment, this type of infusion, defined as the “Usher regimen”, started to be widely adopted in neonatal care. Nonetheless, in the following years, further researches demonstrated that the administration of SB in asphyxiated neonates was not affecting the acid–base balance in the first 24 hours [9], and that there was insufficient evidence from randomized controlled trials to support or refute the use of SB during resuscitation of infants at birth [10]. Furthermore, studies conducted on adult patients evidenced that administration of SB during cardio-pulmonary resuscitation could be detrimental to the myocardial function, due to the worsening of intracellular acidosis related to carbon dioxide accumulation, increased hyperosmolality, extracellular alkalosis and reduced coronary perfusion pressure [3,11]. Thus, since the 2000 update, the International guidelines for neonatal resuscitation did not suggest to use SB during neonatal resuscitation any longer [12]. However, one shall also mention that other authors are still permissive towards SB therapy [13].

Further researches also showed how the administration of SB could increase the risk of death and intraventricular hemorrhage in preterm infants [4, 5, 14]. In a recent retrospective study, Katheria et al. showed how SB administration in extremely preterm infants does not act on the cardiac output in the short term, but leads to transient fluctuations in cerebral and cardiovascular hemodynamics that could cause dangerous effects on the weak brain vessels of such patients [15]. An increased concentration of CO₂ (a potent cerebral vasodilator) and greater blood osmolality (resulting in a flow of intracellular water into the extracellular space) have been suggested as possible co-factors for the cerebral blood flow modifications following SB infusion [16].

Our survey evidences the lack of well-defined pH, BE and lactate thresholds adopted by Italian NICUs for the correction of MA with SB.

Such variability could also be explained by means of different criteria used to define neonatal MA in studies thereof [17-19]. Moreover, normal arterial lactate values are influenced by the hours of life of the infant, with described thresholds ranging from more than 3.8 mmol/l (at 48 hrs.) to over 1.5 mmol/l (after 96 hrs.) [20].
Around 70% of units that commonly treat MA, when needed, administer “half dose” of the SB amount determined by the classic formula proposed in 1960 by Astrup to correct the BE deficit [21]. In addition, the heterogeneity of SB dilution and administration practices observed reflects the largely arbitrary recommendations that can be found in literature [3, 4, 17, 22].

Intravenous SB solutions are highly hypertonic. The 1:1 dilution is the most used by the surveyed centers and frequently recommended [17-22], yet still being hypertonic.

Evidence is conflicting even with reference to the suggested duration of SB infusions. A systematic review in 2002 reported no differences when comparing rapid vs. slow or no correction [23], whereas, a few years later, other researchers suggested a slow infusion of SB, over a 30-min period, to minimize fluctuations in cerebral blood flow of preterm infants [24].

Our survey showed that there is a relevant number of centers (45%) opting for other strategies for the management of MA, rather than the routine administration of SB. Such approach may be considered as being appropriate, also taking into account that the treatment of neonatal MA should preferably rely on the correction of its primary cause, as also suggested by many experts [1, 3, 6, 11]. Another strategy to deal with chronic MA of preterm infants could be to add buffer salt, such as potassium lactate or sodium acetate, to the PN [25] - a practice reported as being used by 37.6% of the surveyed NICUs.

Preterm infants can be frequently exposed to an excessive chloride intake [26] with subsequent hyperchloremia that can constitute a cause of MA, particularly in premature infants, because of the negative effect on the neonatal kidney capability of eliminating acid load [27]. Thus, limiting chloride infusion and providing sodium and potassium as organic phosphate, sodium acetate-citrate or potassium acetate-citrate within the PN preparation might prevent hyperchloremic metabolic acidosis [28-30]. Moreover, some authors reported as earlier/higher parenteral aminoacid and lipid intakes raised the risk of metabolic acidosis, particularly in babies born less than 24-26 weeks of gestation. Nevertheless, stronger evidence is still needed to further support the mentioned practices.

However, our study includes some limitations. Questions did not distinguish between acute or chronic MA nor between occurrence of such condition in term or preterm infants. Thus, some answers may have been arbitrary and may not have adequately described different strategies adopted. The question regarding the “use of SB only for some pathologies” was not fully clear, and we have received answers both from the units that were using SB as well as those not routinely using it. Finally, answers given by the directors of the NICUs did not always reflect attitudes of every clinician within the unit.

**Conclusions**

The conducted survey highlighted how, in Italian NICUs, SB is a commonly adopted treatment for MA and that prescription criteria, dosage and time of infusion vary widely across centers. According to scientific evidence, management of neonatal MA should be directed towards the diagnosis and solution of the possible underlying disorders, reserving the use of SB only for selected cases, also considering the
severity of its adverse effects and the lack of efficacy-based evidence. It is envisaged that a renewed focus and guidance on behalf of scientific societies on the suitable management of MA would likely contribute to harmonizing the current heterogeneity of practices, reducing the use of potentially unsafe treatments.

**Abbreviations**

- base excess (BE)
- Italian society of neonatology (SIN)
- metabolic acidosis (MA)
- neonatal intensive care unit (NICU)
- parenteral nutrition (PN)
- sodium bicarbonate (SB)
- standard deviation (SD)

**Declarations**

**Acknowledgments**

The authors would like to thank their colleagues from the Italian NICUs that responded to the survey. (List of surveyed NICUs in Supplementary file 2).

**Statement of financial support**

None.

**Authors’ contributions**

All authors read and approved the final manuscript; all authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

LM (Massenzi): organised and performed the survey; is responsible for conceiving the study and writing the article; is presently the secretary of the SIN neonatal pharmacotherapy study group. RA (Aueri): organised and performed the survey; is responsible for conceiving the study and writing the article. LM and RA (Aueri) contributed equally to this work. SD (Donno): wrote the statistical analysis plan, cleaned and analysed the data, and drew the figures. RA (Agostino): organised and performed the survey; is responsible for conceiving the study and reviewing the article; is a former secretary of the SIN neonatal
pharmacotherapy study group. AD (Dotta): organised and performed the survey; is responsible for conceiving the study and reviewing the article; was the secretary of the SIN neonatal pharmacotherapy study group at the moment of the study.

**Availability of data and material**

The datasets used and analysed during the current study data are available from the Neonatal Pharmacotherapy Study Group of the Italian Society of Neonatology (SIN) on reasonable request and with permission of the Italian Society of Neonatology board.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

No fundings were necessary for this study.

Thanks to Miss Liza Zinzi for her precious help.

**References**

1. Collins A, Sahni R. Uses and misuses of sodium bicarbonate in the neonatal intensive care unit. Semin Fetal Neonatal Med. 2017;22:336-41.

2. Ammari AN, Schulze KF. Uses and abuses of sodium bicarbonate in the Neonatal Intensive Care Unit. Curr Opin Pediatr. 2002;14:151-6.

3. Aschener JL, Poland RL. Sodium Bicarbonate: basically useless therapy. Pediatrics. 2008;122:831-5.

4. Berg CS, Barnette AR, Myers BJ, Shimony MK, Barton AW, et al. Sodium bicarbonate administration and outcome in preterm infants. J Pediatr. 2010;157:684-7.

5. Papile LA, Burstein J, Burstein R. Relationship of intravenous sodium bicarbonate infusions and cerebral intraventricular hemorrhage. J Pediatr. 1978;93:834-6.

6. Saenz P, Brugada M, Beatriz de Jongh, Sola A, Torres E, et al. A survey of intravenous sodium bicarbonate in neonatal asphyxia among European neonatologists: gaps between scientific evidence and clinical practice. Neonatology. 2011;99:170-6.
7. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6:274-85.

8. Usher R. Reduction of mortality from respiratory distress syndrome of prematurity with early administration of intravenous glucose and sodium bicarbonate. Pediatrics. 1963;32:966-75.

9. Murki, S, Kumar P, Lingappa, L, Narang A. Effect of a single dose of sodium bicarbonate given during neonatal resuscitation at birth on the acid–base status on first day of life. J Perinatol. 2004;24:696-9.

10. Beveridge CJE, Wilkinson AR. Sodium bicarbonate infusion during resuscitation of infants at birth. Cochrane Database Syst Rev. 2006;(1):CD004864.

11. Simma B, Kirpalani H. Sodium Bicarbonate-the swings and roundabouts will not stop without randomized evidence. Crit Care Med. 2013;41:2242-3.

12. Niermeyer S, Kattwinkel J, Van Reempts P, Nadkarni V, Phillips B, et al. International guidelines for neonatal resuscitation: an excerpt from Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: international consensus on science. Pediatrics. 2000;106:E29.

13. Wyllie J, Ainsworth S. What is new in the European and UK neonatal resuscitation guidance? Arch Dis Child Fetal Neonatal Ed. 2016;101:F469-F473.

14. Usher R. Comparison of rapid versus gradual correction of acidosis in RDS of prematurity. Pediatr Res. 1967;3:221.

15. Katheria AC, Brown MK, Hassan K, Poeltler DM, Patel DA, et al. Hemodynamic effects of sodium bicarbonate administration. J Perinatol. 2017;37:518-20.

16. Buckley EM, Naim MY, Lynch JM, Goff DA, Schwab PJ, et al. Sodium bicarbonate causes dose-dependent increases in cerebral blood flow in infants and children with single-ventricle physiology. Pediatr Res. 2013;73:668-73.

17. Johnson PJ. Sodium bicarbonate use in the treatment of acute neonatal lactic acidosis: benefit or harm? Neonatal Netw. 2011;30:199-205.

18. Bourchier D, Weston PJ. Metabolic acidosis in the first 14 days of life in infants of gestation less than 26 weeks. Eur J Pediatr. 2015;174:49-54.

19. Seri I. Acid-base homeostasis in the fetus and newborn. In: Oh W, Guignard JP, Baumgart S, editors. Nephrology and fluid electrolyte physiology: neonatology questions and controversies. 1st ed. Philadelphia: Saunders; 2008. p. 66-75.

20. Lorenz JM, Kleinman LI, Markarian K, Oliver M, Fernandez J. Serum anion gap in the differential diagnosis of metabolic acidosis in critically ill newborns. J Pediatr. 1999;135:751-5.

21. Astrup P, Jorgensen K, Andersen OS, Engel K. The acid-base metabolism; a new approach. Lancet. 1960;1:1035.

22. Howell JH. Sodium bicarbonate in perinatal setting-revisited. Clin Perinatol. 1987;14:807-16.

23. Kecskes ZB, Davies MW. Rapid correction of early metabolic acidaemia in comparison with placebo, no intervention or slow correction in LBW infants. Cochrane Database Syst Rev.2002;(1):CD002976.
24. van Alfen-van der Velden AAEM, Hopman LCW, Klaessens JHGM, Feuth T, Sengers RCA, et al. Effects of rapid versus slow infusion of sodium bicarbonate on cerebral hemodynamics and oxygenation in preterm infants. Biol Neonate. 2006;90:122-7.

25. Bonsante F, Gouyon JB, Robillard PY, Gouyon B, Iacobelli S. Early optimal parenteral nutrition and metabolic acidosis in very preterm infants. PLoS One. 2017;12:e0186936.

26. Kermorvant-Duchemin E, Iacobelli S, Eleni-Dit-Trolli S, Bonsante F, Kermorvant C, et al. Early chloride intake does not parallel that of sodium in extremely-low-birth-weight infants and may impair neonatal outcomes. J Pediatr Gastroenterol Nutr. 2012;54:613-9.

27. Seifter JL. Integration of acid-base and electrolyte disorders. N Engl J Med. 2014;371:1821-31.

28. Peters O, Ryan S, Matthew L, Cheng K, Lunn J. Arch Dis Child Fetal Neonatal Ed. 1997;77:F12-F15.

29. Senterre TT, Terrin G, De Curtis M, Rigo J. Parenteral nutrition in premature infants. In: Guandalini S, Dhawan A, Branski D, editors. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition: a Comprehensive Guide to Practice. Basel: Springer International Publishing; 2016. p. 73-86.

30. Darmaun D, Lapillone A, Simeoni U, Picaud JC, Rozé JC, et al. Parenteral nutrition for preterm infants: Issues and strategy. Arch Pediatr. 2018;25:286-94.

Tables

Table 1. Criteria for treating MA with SB.

Blood gas analysis thresholds adopted for the correction of MA with SB.

| pH | Base Excess | Lactate |
|----|-------------|---------|
| ≤7.10 | 21 (33.9) | 44 (69.8) | no thresholds |
| ≤7.20 | 32 (51.6) | 11 (17.5) | >5mmol/l |
| no thresholds | 5 (8.1) | 5 (7.9) | >2mmol/l |
| ≤7.30 | 3 (4.8) | 2 (3.2) | |
| other | 1 (1.6) | 1 (1.6) | |
| Total answers | 62 (100) | 63 (100) | 62 (100) |

Table 2. SB dose, preparation and administration practices.
| Dose                      | Diluent                               | Dilution | Administration time |
|--------------------------|---------------------------------------|----------|---------------------|
| ml of SB = kg × BE × 0.3 / 2 | sterile water for injection           | 1:1      | 30-60 min           |
|                          |                                       | n (%)    | (69.8)              |
|                          |                                       | 57       | (90.5)              |
|                          |                                       | 55       | (87.3)              |
|                          |                                       | 38       | (61.3)              |
| ml of SB = kg × BE × 0.3 / 3 | normal saline                         | 1:2      | ≤30 min             |
|                          |                                       | n (%)    | (12.7)              |
|                          |                                       | 8        | (7.9)               |
|                          |                                       | 6        | (9.5)               |
|                          |                                       | 17       | (27.4)              |
| ml of SB = kg × BE × 0.3 | other                                 | 1:3      | bolus + slow infusion |
|                          |                                       | n (%)    | (9.5)               |
|                          |                                       | 6        | (1.6)               |
|                          |                                       | 17       | (8.1)               |
| 1mEq/kg                  | other                                 | 3-4 hours or more |
|                          |                                       | n (%)    | (6.3)               |
|                          |                                       | 4        | (1.6)               |
|                          |                                       | 2        | (3.2)               |

Total answers 63 (100) 63 (100) 63 (100) 63 (100) 62 (100) 63 (100) 63 (100) 63 (100) 63 (100) 63 (100) 63 (100) 63 (100)

Figures

![Figure 1]

Figure 1
Use of SB for treating MA. Surveyed Italian NICUs (n = 117) are classified according to unit’s characteristics. Differences among groups are not significant (p value: 0.51).

Figure 2

Therapeutic strategies adopted for treating MA in the NICUs not using SB. (a) Percentage of NICUs (n = 53) using each strategy. (b) Percentage of NICUs (n = 53) adopting one or more therapeutic strategies.
Figure 3

Buffer salts in PN. Percentage of NICUs (n = 117) using buffer salts in PN classified according to unit’s characteristics. Differences among groups are not significant (p value: 0.76).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FileS1LettertoNICUdirectorswithquestionnaire.pdf
- FileS2ListofcontactedNICUs.pdf
- FileS3QuestionnairetranslatedtoEnglish.doc